SynchroPET

About:

MRI Compatible Positron Emission Tomography P.E.T. Scanners for human imaging and pre-clinical small animal research.

Twitter/X: SynchroPET

Top Investors: Creative Destruction Lab (CDL), New York Angels, Topspin Partners, AngelFire Ventures, Long Island Angel Network

Description:

We build the smallest Positron Emission Tomography (PET) Scanners in medical imaging and research. Our first device promises to disrupt the nuclear imaging market by providing a non invasive input function that makes all PET scanners more quantitative and better at diagnosis and treatment of diseases like cancer, alzheimers, and parkinson's. This new quantitative data opens up and accelerates new possibilities in personalized medical treatments and cures.

Total Funding Amount:

$1.48M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Stony Brook, New York, United States

Founded Date:

2013-03-01

Contact Email:

marc(AT)synchropet.com

Founders:

Aaron McFarland, David Smith, Marc Alessi

Number of Employees:

1-10

Last Funding Date:

2021-01-01

IPO Status:

Private

Industries: